Previous 10 | Next 10 |
Noteworthy events during the week of November 10 - 16 for healthcare investors. More news on: Ocular Therapeutix, Inc., Y-mAbs Therapeutics, Inc., Amarin Corporation plc, Healthcare stocks news, , Read more ...
Amarin Corporation (AMRN), recently announced Q3 earnings with a beat on EPS and revenue. This was another record quarter for Amarin, who pulled in $112.4M in revenue while limiting their net loss to $3.5M . This record quarter was fueled by Vascepa's growth in number of scripts and num...
Amarin (NASDAQ: AMRN) , a $5.7 billion biotech stock focused on treating cardiovascular diseases, has recently become one of the most-watched stocks in the healthcare sector. Its signature omega-3 fish oil drug, Vascepa, has been used for patients with high triglyceride levels for a while. ...
Shares of America's favorite fish-oil stock, Amarin (NASDAQ: AMRN) , have risen sixfold since the company released surprisingly positive results from the Reduce-It study last September. In a nutshell, the company's only product, a fish-oil capsule called Vascepa, appears to lower the risk of ...
In its third-quarter report , Amarin (NASDAQ: AMRN) topped FactSet's consensus revenue estimate ($112.4 million versus $110.04 million) and non-GAAP adjusted earnings-per-share forecast ($0.01, versus a $0.04 loss). Even so, Amarin's shares still hit the skids during Tuesday'...
Amarin Corporation plc (AMRN) Q3 2019 Earnings Conference Call November 5, 2019 7:30 AM ET Company Participants Elisabeth Schwartz – Senior Director, Investor Relations John Thero – President and Chief Executive Officer Mike Kalb – Senior Vice President and C...
The following slide deck was published by Amarin Corporation plc in conjunction with their 2019 Q3 earnings Read more ...
Image source: The Motley Fool. Amarin Corporation plc (NASDAQ: AMRN) Q3 2019 Earnings Call Nov 5, 2019 , 7:30 a.m. ET Operator Continue reading
Amarin (NASDAQ: AMRN ) Q3 results : More news on: Amarin Corporation plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Amarin (NASDAQ: AMRN ): Q3 Non-GAAP EPS of $0.01 beats by $0.05 ; GAAP EPS of -$0.01 beats by $0.03 . Revenue of $112.4M (+103.3% Y/Y) beats by $2.36M . Shares +0.6% PM. Press Release More news on: Amarin Corporation plc, Earnings news and commentary, Healthcare stocks news, ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...